These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

47 related items for PubMed ID: 12730544

  • 21. The prevalence of patients with rheumatoid arthritis in the West Midlands fulfilling the BSR criteria for anti-tumour necrosis factor therapy: an out-patient study.
    Yee CS, Filer A, Pace A, Douglas K, Situnayake D, Rowe IF, West Midlands Rheumatology Services and Training Committee.
    Rheumatology (Oxford); 2003 Jul; 42(7):856-9. PubMed ID: 12730544
    [Abstract] [Full Text] [Related]

  • 22. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL, Watson KD, Silman AJ, Symmons DP, British Society for Rheumatology Biologics Register.
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [Abstract] [Full Text] [Related]

  • 23. The impact of escalating conventional therapy in rheumatoid arthritis patients referred for anti-tumour necrosis factor-alpha therapy.
    Bingham SJ, Buch MH, Tennant A, Emery P.
    Rheumatology (Oxford); 2004 Mar; 43(3):364-8. PubMed ID: 14657509
    [Abstract] [Full Text] [Related]

  • 24. Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis.
    Sokka T, Pincus T.
    Arthritis Rheum; 2003 Feb; 48(2):313-8. PubMed ID: 12571838
    [Abstract] [Full Text] [Related]

  • 25. Rituximab therapy in patients with rheumatoid arthritis refractory or with contraindication to anti-tumour necrosis factor drugs: real-life experience in Finnish patients.
    Valleala H, Korpela M, Möttönen T, Hienonen-Kempas T, Kauppi M, Hannonen P, Leirisalo-Repo M.
    Scand J Rheumatol; 2009 Feb; 38(5):323-7. PubMed ID: 19585384
    [Abstract] [Full Text] [Related]

  • 26. A comparison of response criteria to evaluate therapeutic response in patients with juvenile idiopathic arthritis treated with methotrexate and/or anti-tumor necrosis factor alpha agents.
    Lurati A, Pontikaki I, Teruzzi B, Desiati F, Gerloni V, Gattinara M, Cimaz R, Fantini F.
    Arthritis Rheum; 2006 May; 54(5):1602-7. PubMed ID: 16646003
    [Abstract] [Full Text] [Related]

  • 27. The prevalence of patients with rheumatoid arthritis in the West Midlands fulfilling the BSR criteria for anti-tumour necrosis factor therapy: an out-patient study.
    Yee CS, Filer A, Pace A, Douglas K, Situnayake D, Rowe IF, West Midlands Rheumatology Services and Training Committee.
    Rheumatology (Oxford); 2003 Jul; 42(7):856-9. PubMed ID: 12730544
    [Abstract] [Full Text] [Related]

  • 28. Biologics in rheumatoid arthritis.
    Sharma PK, Hota D, Pandhi P.
    J Assoc Physicians India; 2004 Mar; 52():231-6. PubMed ID: 15636315
    [Abstract] [Full Text] [Related]

  • 29. [Lesson from ACR guidelines for management of RA].
    Abe T.
    Nihon Rinsho; 2005 Jan; 63 Suppl 1():431-8. PubMed ID: 15799394
    [No Abstract] [Full Text] [Related]

  • 30. Combination DMARD therapy for rheumatoid arthritis.
    Kremer JM.
    Manag Care; 2001 Jul; 10(7 Suppl):10-4. PubMed ID: 11729428
    [No Abstract] [Full Text] [Related]

  • 31. How early should psoriatic arthritis be treated with a TNF-blocker?
    Harty L, Veale DJ.
    Curr Opin Rheumatol; 2010 Jul; 22(4):393-6. PubMed ID: 20520552
    [Abstract] [Full Text] [Related]

  • 32. Patient-tailored therapy in rheumatoid arthritis: an editorial review.
    Scherer HU, Dörner T, Burmester GR.
    Curr Opin Rheumatol; 2010 May; 22(3):237-45. PubMed ID: 20177384
    [Abstract] [Full Text] [Related]

  • 33. Criteria for TNF-targeted therapy in rheumatoid arthritis: estimates of the number of patients potentially eligible.
    Kvien TK, Uhlig T, Kristiansen IS.
    Drugs; 2001 May; 61(12):1711-20. PubMed ID: 11693461
    [Abstract] [Full Text] [Related]

  • 34. Rheumatology. Part 2: The role of medication.
    Byrne J.
    Prof Nurse; 1999 Feb; 14(5):353-8. PubMed ID: 10205553
    [Abstract] [Full Text] [Related]

  • 35. Management of refractory rheumatoid arthritis.
    van de Putte LB, Kroot EJ, van Riel PL.
    Rheumatology (Oxford); 1999 Nov; 38 Suppl 2():32-4. PubMed ID: 10646488
    [Abstract] [Full Text] [Related]

  • 36. Updated pharmacological management of rheumatoid arthritis for women before, during, and after pregnancy, reflecting recent guidelines.
    Murray KE, Moore L, O'Brien C, Clohessy A, Brophy C, Minnock P, FitzGerald O, Molloy ES, Mongey AB, Higgins S, Higgins MF, Mc Auliffe FM, Veale DJ.
    Ir J Med Sci; 2019 Feb; 188(1):169-172. PubMed ID: 29748892
    [Abstract] [Full Text] [Related]

  • 37. Therapeutic drug monitoring in rheumatic diseases: utile or futile?
    Stamp LK, Barclay M.
    Rheumatology (Oxford); 2014 Jun; 53(6):988-97. PubMed ID: 24196384
    [Abstract] [Full Text] [Related]

  • 38. Lactation and Management of Postpartum Disease.
    Bermas BL.
    Rheum Dis Clin North Am; 2017 May; 43(2):249-262. PubMed ID: 28390567
    [Abstract] [Full Text] [Related]

  • 39. Robin goodfellow.
    Rheumatology (Oxford); 2001 Jul; 40(7):838. PubMed ID: 11477300
    [No Abstract] [Full Text] [Related]

  • 40. [Highlights of rheumatology 1999: new developments between immunology and pain of movement mechanisms].
    Frey D, Tyndall A.
    Schweiz Med Wochenschr; 2000 Jan 11; 130(1-2):8-13. PubMed ID: 10670038
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 3.